Abbott Korea, which has been in a dispute with the Ministry of Health and Welfare, immediately filed an appeal against the administrative court ruling by raising the issue of lowering the additional revaluation of the Rytmonorm SR series. Leo Pharma, which raised the issue together last year, decided to avoid legal confrontation with the government and abandoned the appeal.

As a result, the drug price of Leo Pharma's seven items has been lowered as planned by the government from the 15th, and the drug price of Abbott's three items will be temporarily maintained due to the suspension of execution. Abbott appealed to the High Court for a total of three products containing Rytmonorm SR 225mg, 325mg and 425